Cystic Fibrosis Patient Testimony on Orkambi

admin avatar

by admin |

Share this article:

Share article via email

Orkambi is a combination therapy for treatment of cystic fibrosis. The FDA approval for the therapy was announced on July 2nd, 2015.

This is Kate Marshall’s Orkambi testimony before the Open Public Hearing OPH portion of the May 12, 2015 Pulmonary-Allergy Drugs Advisory Committee (PADAC) meeting in Washington, DC.

Kate is 15 years old and has two copies of the D508 gene, which Orkambi, (the combination of Ivacaftor and Lumacaftor) treats.

Learn more about Orkambi here:

Read all the latest news about Orkambi here:

Featured Column

The Benefits of Being Sick

A banner for Lara's column, depicting a car on a road trip winding through a forest.
As columnist Lara Govendo reflects on her journey through CF and transplant, she realizes there are a surprising number of benefits.

Read the Column

Your CF Community

Visit the Cystic Fibrosis News Today forums to connect with others in the CF community.